Bifogade filer
Kurs
+1,18%
Likviditet
44,8 MNOK
Kalender
Est. tid* | ||
2025-10-30 | 07:40 | Kvartalsrapport 2025-Q3 |
2025-08-15 | 07:40 | Kvartalsrapport 2025-Q2 |
2025-06-04 | N/A | X-dag halvårsutdelning VISTN 1.25 |
2025-05-22 | N/A | Årsstämma |
2025-04-25 | - | Kvartalsrapport 2025-Q1 |
2025-02-13 | - | Bokslutskommuniké 2024 |
2024-11-06 | - | X-dag halvårsutdelning VISTN 0.5 |
2024-10-31 | - | Kvartalsrapport 2024-Q3 |
2024-08-23 | - | Kvartalsrapport 2024-Q2 |
2024-06-05 | - | X-dag halvårsutdelning VISTN 0.5 |
2024-05-23 | - | Årsstämma |
2024-04-24 | - | Kvartalsrapport 2024-Q1 |
2024-02-16 | - | Bokslutskommuniké 2023 |
2024-01-23 | - | X-dag ordinarie utdelning VISTN 0.75 NOK |
2023-10-25 | - | Kvartalsrapport 2023-Q3 |
2023-08-23 | - | Kvartalsrapport 2023-Q2 |
2023-05-23 | - | X-dag ordinarie utdelning VISTN 0.00 NOK |
2023-05-22 | - | Årsstämma |
2023-04-27 | - | Kvartalsrapport 2023-Q1 |
2023-02-17 | - | Bokslutskommuniké 2022 |
2022-10-26 | - | Kvartalsrapport 2022-Q3 |
2022-08-19 | - | Kvartalsrapport 2022-Q2 |
2022-05-24 | - | X-dag ordinarie utdelning VISTN 0.00 NOK |
2022-05-19 | - | Årsstämma |
2022-04-27 | - | Kvartalsrapport 2022-Q1 |
2022-02-17 | - | Bokslutskommuniké 2021 |
2021-10-28 | - | Kvartalsrapport 2021-Q3 |
2021-08-19 | - | Kvartalsrapport 2021-Q2 |
2021-05-21 | - | X-dag ordinarie utdelning VISTN 0.50 NOK |
2021-05-20 | - | Årsstämma |
2021-04-23 | - | Kvartalsrapport 2021-Q1 |
2021-02-19 | - | Bokslutskommuniké 2020 |
2020-10-30 | - | Kvartalsrapport 2020-Q3 |
2020-08-28 | - | Kvartalsrapport 2020-Q2 |
2020-06-24 | - | Extra Bolagsstämma 2020 |
2020-05-20 | - | X-dag ordinarie utdelning VISTN 1.00 NOK |
2020-05-19 | - | Årsstämma |
2020-04-23 | - | Kvartalsrapport 2020-Q1 |
2020-02-28 | - | Bokslutskommuniké 2019 |
2019-10-25 | - | Kvartalsrapport 2019-Q3 |
2019-08-29 | - | Kvartalsrapport 2019-Q2 |
2019-05-23 | - | X-dag ordinarie utdelning VISTN 0.00 NOK |
2019-05-22 | - | Årsstämma |
2019-04-25 | - | Kvartalsrapport 2019-Q1 |
2019-02-19 | - | Bokslutskommuniké 2018 |
2018-10-25 | - | Kvartalsrapport 2018-Q3 |
2018-08-30 | - | Kvartalsrapport 2018-Q2 |
2018-05-25 | - | X-dag ordinarie utdelning VISTN 1.00 NOK |
2018-05-08 | - | Årsstämma |
2018-04-26 | - | Kvartalsrapport 2018-Q1 |
2018-02-27 | - | Bokslutskommuniké 2017 |
2017-11-03 | - | X-dag bonusutdelning VISTN 7 |
2017-11-02 | - | Extra Bolagsstämma 2017 |
2017-10-27 | - | Kvartalsrapport 2017-Q3 |
2017-08-31 | - | Kvartalsrapport 2017-Q2 |
2017-05-26 | - | X-dag ordinarie utdelning VISTN 1.00 NOK |
2017-05-24 | - | Årsstämma |
2017-04-26 | - | Kvartalsrapport 2017-Q1 |
2017-02-28 | - | Bokslutskommuniké 2016 |
2016-10-31 | - | Kvartalsrapport 2016-Q3 |
2016-08-30 | - | Kvartalsrapport 2016-Q2 |
2016-05-25 | - | X-dag ordinarie utdelning VISTN 0.60 NOK |
2016-05-24 | - | Årsstämma |
2016-04-28 | - | Kvartalsrapport 2016-Q1 |
2016-02-23 | - | Bokslutskommuniké 2015 |
2015-10-29 | - | Kvartalsrapport 2015-Q3 |
2015-08-26 | - | Kvartalsrapport 2015-Q2 |
Beskrivning
Land | Norge |
---|---|
Lista | Oslo Bors |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
Ferncliff Listed Dai AS has on 6 May 2025 sold 1,234,280 shares in Vistin Pharma ASA at NOK 22.50 per share.
Saga Pure ASA has on 6 May 2025 sold 700,000 shares in Vistin Pharma ASA at NOK 22.50 per share.
After the transaction Saga Pure ASA and Ferncliff Listed Dai AS has no holding of shares in Vistin Pharma ASA. Øystein Stray Spetalen and associated parties have a holding of 331,886 shares in Vistin Pharma ASA.
Saga Pure ASA and Ferncliff Listed Dai AS are closely associated with board member Øystein Stray Spetalen.
The ownerhip by Øystein Stray Spetalen and associated companies have after these transactions surpassed below ownership of 5%.
At the same time Intertrade Shipping AS, closely associated with Chairman Øyvin A. Brøymer, has purchased 1 934 280 shares, equal to the number of shares sold by Ferncliff Listed Dai AS and Saga Pure ASA, at a price of NOK 22.50 per share. After this transaction Intertrade Shipping AS holds a total number of 14 509 280 shares, equal to 32,72% of the shares in Vistin Pharma ASA.
Please see the attached notification forms.
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act